Liposomal NADH 70% Coenzyme 1 Energy Supplement

Product Overview

Liposomal NADH 70% is a premium-grade, liposomal-encapsulated form of reduced β-nicotinamide adenine dinucleotide (NADH), standardized to ≥70% active content (HPLC). NADH, also known as coenzyme I, is the reduced form of NAD⁺ and serves as the primary electron donor in the mitochondrial electron transport chain, directly fueling oxidative phosphorylation and ATP synthesis. Each molecule of NADH provides sufficient energy to generate approximately 2.5–3 molecules of ATP, making it a critical determinant of cellular energy output.

Derived from enzymatic synthesis and encapsulated within a phospholipid bilayer composed of lecithin and cholesterol, this product addresses the fundamental limitation of conventional NADH: its instability and poor oral bioavailability.

Why Liposomal Technology?

NADH is an intrinsically unstable molecule—highly sensitive to oxygen, heat, light, and moisture—and degrades rapidly under gastric acid conditions. Conventional oral NADH achieves only approximately 20% bioavailability due to enzymatic degradation in the gastrointestinal tract and limited passive absorption.

Liposomal encapsulation provides three critical advantages:

1. Gastric Protection — The phospholipid bilayer shields NADH from acid degradation, ensuring intact transit through the stomach and precise release in the small intestine.

2. Enhanced Cellular Uptake — Liposomes fuse directly with intestinal cell membranes, bypassing passive diffusion pathways for efficient cytoplasmic delivery. This mechanism elevates bioavailability to as high as 95%.

3. Room-Temperature Stability — While conventional NADH requires cold-chain storage at −20°C and degrades within days at ambient temperature, liposomal NADH maintains stability at 25°C for up to 24 months, with NADH content remaining above 92.64% after storage.

Key Features

• High Potency — Standardized to ≥70% NADH (HPLC), ensuring consistent and reliable active content.

• Ultra-High Bioavailability — Liposomal delivery achieves up to 95% bioavailability compared to approximately 20% for conventional NADH.

• Superior Stability — Phospholipid encapsulation confers room-temperature stability for up to 24 months without cold-chain requirements.

• Rapid Release Profile — Drug release rate reaches 80% within 2 hours at pH 6.8, simulating intestinal conditions.

• Water-Dispersible — Easily soluble in water, forming a uniform suspension; dispersible in phosphate-buffered saline (PBS).

• Clean-Label Compatible — Formulation can be gluten-free, lactose-free, and free of artificial colors; suitable for vegetarian applications.

Application & Formulation Guidance

Product Specifications

Recommended Storage

Store in a cool, dry place away from direct sunlight and moisture. Keep container tightly sealed when not in use. Optimal storage temperature: below 25°C. Refrigerated storage (2–8°C) extends shelf life to 18–24 months.

NADH Encyclopedia — Scientific Background

What Is NADH?

Nicotinamide adenine dinucleotide (NADH), commonly referred to as reduced coenzyme I, is the reduced form of nicotinamide adenine dinucleotide (NAD⁺). The abbreviation NADH denotes Nicotinamide Adenine Dinucleotide with H (hydrogen). NADH and NAD⁺ constitute a redox pair central to cellular Energy Metabolism, with NADH acting as the electron donor and NAD⁺ as the electron acceptor in oxidation-reduction reactions.

NAD was first discovered in 1906 by Nobel laureate Arthur Harden, with systematic research into its functions beginning in 1935. The molecule exists in all living cells and is classified as a dinucleotide because it consists of two nucleotides joined through their phosphate groups—one containing an adenine nucleobase and the other containing nicotinamide.

Biochemical Role in Cellular Energy

The Electron Transport Chain

NADH is produced in glycolysis and the citric acid cycle of cellular respiration, functioning as a biological hydrogen carrier and electron donor. In the mitochondrial matrix, NADH diffuses to the inner mitochondrial membrane, where it passes electrons to the flavin mononucleotide (FMN) of Complex I (NADH dehydrogenase). The oxidation of one molecule of NADH leads to the synthesis of approximately 3 molecules of ATP through oxidative phosphorylation.

The oxidation of NADH is coupled to the transport of protons across the mitochondrial inner membrane into the intermembrane space, creating an osmotic gradient whose energy release drives ATP synthesis by ATP synthase.

Tissue Distribution

The concentration of NADH in tissues correlates directly with energy demand:

Organs requiring higher energy output maintain correspondingly higher NADH content.

Physiological Functions

Cellular Energy Production

NADH serves as a rate-limiting cofactor in mitochondrial ATP synthesis. The amount of NADH present in a cell is directly related to its energy production capacity—the more NADH available, the more energy the cell can generate. This makes NADH particularly relevant for tissues with high metabolic demand, including cardiac muscle, skeletal muscle, and neural tissue.

Antioxidant Defense

Supplementing liposomal NADH elevates intracellular NAD⁺ levels, which in turn activates the sirtuin family of NAD⁺-dependent deacetylases. Sirtuins—particularly SIRT1 and SIRT2—are recognized as “anti-aging” enzymes that regulate DNA repair, mitochondrial function, and cellular stress responses. Studies indicate that NADH supplementation can upregulate SIRT2-dependent signaling pathways, promoting cellular maintenance and longevity-associated gene expression.

Additionally, NADH demonstrates direct free radical scavenging properties. Under specific dosing conditions, free radical clearance rates approach 100%, reducing oxidative stress damage to cellular membranes, proteins, and nucleic acids.

Neuroprotection and Neurotransmitter Synthesis

NADH promotes the synthesis of neurotransmitters and has demonstrated neuroprotective effects in clinical research. In open-label trials involving 34 Parkinson‘s disease patients, 21 patients (61.7%) showed very good improvement (greater than 30% disability reduction), while 13 patients (38.3%) showed moderate improvement (up to 30%). Parenteral NADH application has been shown to stimulate endogenous levodopa biosynthesis, providing clinical benefit for Parkinsonian patients.

Cardiovascular Support

Animal studies demonstrate that NADH supplementation for 8 weeks reduces total cholesterol by approximately 30%, with significant reductions in systolic blood pressure observed after 11 weeks. These effects are attributed to NADH’s role in regulating lipid metabolism and its antioxidant protection of vascular endothelium.

Clinical Evidence

A systematic review of 10 randomized clinical trials involving 489 participants evaluated NADH supplementation across multiple clinical conditions, including chronic fatigue syndrome, Parkinson’s disease, Alzheimer‘s disease, overweight, and postmenopausal prediabetes. Key findings include:

• Fatigue Reduction — A randomized, double-blind, placebo-controlled trial demonstrated that NADH supplementation (20 mg daily) significantly reduced fatigue in chronic fatigue syndrome patients, with response rates of approximately 30% versus 8% for placebo. A separate study combining NADH with CoQ10 showed a 30.7% reduction in overall fatigue within 60 days (P < 0.001).

• Quality of Life — Oral NADH administration was associated with increased general quality of life, decreased anxiety conditions, reduced maximum heart rate after stress testing, and improved muscle insulin sensitivity.

• Physical Endurance — Oral NADH supplementation significantly enhances physical endurance, aerobic capacity, and cardiovascular recovery in healthy young adults under stress, without altering leukocyte metabolic markers.

• Safety Profile — NADH supplementation is generally well-tolerated with no serious adverse events reported in clinical trials. The most commonly associated side effects are mild and include muscle pain, nervous disorders, fatigue, sleep disturbance, and headaches. All adverse events cataloged in clinical studies did not present a serious risk to participant health.

The Bioavailability Challenge

Despite its central role in cellular metabolism, native NADH presents significant formulation challenges. The molecule is hygroscopic and notably sensitive to oxygen, heat, light, and moisture, requiring protective handling, stabilization, or encapsulation in commercial applications. Conventional oral NADH achieves only approximately 20% bioavailability due to degradation in the gastrointestinal tract and limited passive diffusion across intestinal epithelium.

Liposomal encapsulation addresses these limitations through a biomimetic phospholipid bilayer that protects NADH during digestive transit, facilitates direct membrane fusion for cellular uptake, and provides sustained release kinetics. The result is a bioavailability enhancement from approximately 20% to 95%—a critical advancement for clinical efficacy and formulation reliability.

Regulatory Status

NAD, NAD⁺, and NADH are legal dietary supplement ingredients under the U.S. Dietary Supplement Health and Education Act (DSHEA). However, regulatory status varies by region—for example, NAD, NAD⁺, and NADH are currently not permitted as ingredients in listed medicines in Australia. Formulators should verify local regulatory requirements prior to market entry.

425$/KG

345$/KG